Home › Funds › Vivo Capital, LLC › EPRX

Vivo Capital, LLC position in EPRX

Eupraxia Pharmaceuticals Inc · Health Care

Vivo Capital, LLC reported holding 1,350,000 shares of EPRX (Eupraxia Pharmaceuticals Inc) in its Q3 2026 13F filing — a position valued at US$12.3M, representing 1.39% of its reported portfolio and ranking #25 among its reported holdings. Vivo Capital, LLC has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)1.35M sh
Reported value held$12.29M
Portfolio Weight1.39%
First reportedQ3 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Vivo Capital, LLC's EPRX position evolved

Vivo Capital, LLC first disclosed a stake in EPRX in Q3 2025 at 1,350,000 shares (US$8.0M). The position peaked in Q3 2026 at 1,350,000 shares, worth US$12.3M. Across 5 filings, Vivo Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,350,000 shares valued at US$12.3M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 1.35M $7.96M New
Q4 2025 1.35M $10.19M Hold
Q1 2026 1.35M $9.77M Hold
Q2 2026 1.35M $8.92M Hold
Q3 2026 1.35M $12.29M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EPRX and 13F data

EPRX (Eupraxia Pharmaceuticals Inc) is a Health Care company. 70 other funds we track also report a position in EPRX — the largest reported positions include PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M), Ikarian Capital, LLC (US$5.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EPRX

All EPRX fund holders →

FAQ

How long has Vivo Capital, LLC held EPRX?

Vivo Capital, LLC has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Vivo Capital, LLC's current position in EPRX?

As of Q3 2026, Vivo Capital, LLC holds 1.35M shares of EPRX (Eupraxia Pharmaceuticals Inc), valued at $12.29M, representing 1.39% of its reported portfolio and ranking #25.

Has Vivo Capital, LLC been buying or selling EPRX?

In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in EPRX. The position peaked in Q3 2026 at 1.35M shares.

Which other funds hold EPRX?

Other major institutional holders of EPRX include PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, Ikarian Capital, LLC, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.